Literature DB >> 7974308

Why use erythromycin?

R J White.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7974308      PMCID： PMC475225          DOI： 10.1136/thx.49.10.944

Source DB:  PubMed          Journal:  Thorax        ISSN： 0040-6376            Impact factor:   9.139


× No keyword cloud information.
  14 in total

1.  Chemotherapy for infections caused by Haemophilus influenzae: current problems and future prospects.

Authors:  M Powell
Journal:  J Antimicrob Chemother       Date:  1991-01       Impact factor: 5.790

2.  Resistance to erythromycin in group A streptococci.

Authors:  H Seppälä; A Nissinen; H Järvinen; S Huovinen; T Henriksson; E Herva; S E Holm; M Jahkola; M L Katila; T Klaukka
Journal:  N Engl J Med       Date:  1992-01-30       Impact factor: 91.245

3.  More macrolides.

Authors:  M J Wood
Journal:  BMJ       Date:  1991-09-14

4.  Hospital study of adult community-acquired pneumonia.

Authors:  J T Macfarlane; R G Finch; M J Ward; A D Macrae
Journal:  Lancet       Date:  1982-07-31       Impact factor: 79.321

5.  Causes of pneumonia presenting to a district general hospital.

Authors:  R J White; A D Blainey; K J Harrison; S K Clarke
Journal:  Thorax       Date:  1981-08       Impact factor: 9.139

6.  Effect of antibiotics on growth of Mycoplasma pneumoniae Mac.

Authors:  S Arai; K Yoshida; A Izawa; K Kumagai; N Ishida
Journal:  J Antibiot (Tokyo)       Date:  1966-05       Impact factor: 2.649

7.  Prospective study of aetiology and outcome of adult lower-respiratory-tract infections in the community.

Authors:  J T Macfarlane; A Colville; A Guion; R M Macfarlane; D H Rose
Journal:  Lancet       Date:  1993-02-27       Impact factor: 79.321

8.  Prospective study of the aetiology and outcome of pneumonia in the community.

Authors:  M A Woodhead; J T Macfarlane; J S McCracken; D H Rose; R G Finch
Journal:  Lancet       Date:  1987-03-21       Impact factor: 79.321

9.  Legionnaires' disease: description of an epidemic of pneumonia.

Authors:  D W Fraser; T R Tsai; W Orenstein; W E Parkin; H J Beecham; R G Sharrar; J Harris; G F Mallison; S M Martin; J E McDade; C C Shepard; P S Brachman
Journal:  N Engl J Med       Date:  1977-12-01       Impact factor: 91.245

10.  A comparison of clarithromycin with ampicillin in the treatment of outpatients with acute bacterial exacerbation of chronic bronchitis.

Authors:  P M Aldons
Journal:  J Antimicrob Chemother       Date:  1991-02       Impact factor: 5.790
View more
  3 in total

1.  Comparison of amoxycillin and clarithromycin as initial treatment of community-acquired lower respiratory tract infections.

Authors:  J T MacFarlane; J Prewitt; P Gard; A Guion
Journal:  Br J Gen Pract       Date:  1996-06       Impact factor: 5.386

2.  Erythromycin Modification That Improves Its Acidic Stability while Optimizing It for Local Drug Delivery.

Authors:  Erika L Cyphert; Jaqueline D Wallat; Jonathan K Pokorski; Horst A von Recum
Journal:  Antibiotics (Basel)       Date:  2017-04-25

3.  Encapsulation of erythromycin and bacitracin antibiotics into natural sporopollenin microcapsules: antibacterial, cytotoxicity, in vitro and in vivo release studies for enhanced bioavailability.

Authors:  Amro K F Dyab; Mohamed A Mohamed; Noha M Meligi; Shaaban K Mohamed
Journal:  RSC Adv       Date:  2018-09-27       Impact factor: 4.036
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.